anti-doping testing comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
=== Counterfeiting === In major re-export hubs like Singapore, Malaysia and Hong Kong, fish maw is frequently mislabeled as more expensive varieties of fish, due to high profit incentive and the high level of visual similarity between disparately priced species. HK Magazine in 2007 described two incidents of counterfeit fish maw in Hong Kong: one of dried rabbit ear, and the other of shoe rubber.
Cocaine, heroin, cannabis, and other such drugs continued to be legally available without prescription as long as they were labeled. It is estimated that sale of patent medicines containing opiates decreased by 33% after labeling was mandated. In 1906 in Britain and in 1908 in Canada "laws requiring disclosure of ingredients and limitation of narcotic content were instituted". The Harrison Narcotics Tax Act of 1914 restricted the manufacture and distribution of opiates, including laudanum, and coca derivatives in the US. This was followed by France's Loi des stupéfiants in 1916, and Britain's Dangerous Drugs Act in 1920. Laudanum was supplied to druggists and physicians in regular and concentrated versions. For example, in 1915, Frank S. Betz Co., a medical supply company in Hammond, Indiana, advertised Tincture of Opium, U.S.P., for $2.90 per lb., Tincture of Opium Camphorated, U.S.P, for 85 cents per lb., and Tincture of Opium Deodorized, for $2.85 per lb. Four versions of opium as a fluid extract were also offered: (1) Opium, Concentrated (assayed) "For making Tincture Opii (Laudanum) U.S.P. Four times the strength of the regular U.S.P." tincture, for $9.35 per pint; (2) Opium, Camphorated Conc. "1 oz. making 8 ozs. Tr. Opii Camphorated U.S.P (Paregoric)" for $2.00 per pint; (3) Opium, Concentrated (Deodorized and Denarcotized) "Four times the strength of tincture, Used when Tinct. Opii U.S.P. is contraindicated" for $9.50 per pint, and (4) Opium (Aqueous), U.S.P., 1890, "Tr. (assayed) Papaver Somniferum" for $2.25 per pint.
== Availability == There is an overall shortage of antivenom to treat snakebites. Because of this shortage, clinical researchers are considering whether lower doses may be as effective as higher doses in severe neurotoxic snake envenoming. Antivenom undergoes successive price markups after manufacturing, by licencees, wholesalers and hospitals. When weighed against profitability (especially for sale in poorer regions), the result is that many snake antivenoms, world-wide, are very expensive. Availability, from region to region, also varies. Internationally, antivenoms must conform to the standards of pharmacopoeia and the World Health Organization (WHO). Antivenoms have been developed for the venoms associated with the following animals:
=== Amino acid sequence === The linear amino acid sequence of a protein is called the primary structure. The primary structure can be easily determined from the sequence of codons on the DNA gene that codes for it. In most proteins, the primary structure uniquely determines the 3-dimensional structure of a protein in its native environment. An exception is the misfolded prion protein involved in bovine spongiform encephalopathy. This structure is linked to the function of the protein. Additional structural information includes the secondary, tertiary and quaternary structure. A viable general solution to the prediction of the function of a protein remains an open problem. Most efforts have so far been directed towards heuristics that work most of the time.
Sources: en.wikipedia.org
== Appointments == Kahn became the president and director of Joslin in 2000 and held this position until 2007. In 2012, he was appointed Joslin's first Chief Academic Officer. Outside of Joslin, Kahn also held various leadership roles. In 1998 he was appointed chair of the Congressionally-mandated Diabetes Research Working Group (DRWG). This group developed a strategic plan which served as the roadmap for growth of the diabetes research for the United States over the following 10 years. Dr. Kahn also served as chair of Class IV (Biomedical Sciences) of the National Academy of Sciences from 2007 to 2010.
== Pharmacokinetics == Cordycepin readily crosses the blood-brain barrier. It has a very short half-life (between 1 and 2h in cell culture). Pentostatin greatly enhances its clock-resetting effects in cell cultures, likely by preventing deamination.
This competition could alter the post-transcriptional gene regulation (PTGR) of ADME-related genes, leading to indirect modulation of the expression of drug-metabolizing enzymes or transporters and causing DDIs with co-administered drugs. Short hairpin RNAs (shRNAs) may additionally compete with pre-miRNAs for the nuclear export protein Exportin-5 (XPO5) and the cytoplasmic ribonuclease Dicer, disrupting global miRNA biogenesis and posing further DDI risk. The U.S. Food and Drug Administration has issued guidance specific to oligonucleotide therapeutics, recommending assessment of QTc interval prolongation, immunogenicity, organ-impairment effects on PD endpoints, and the potential for RNAi machinery competition as part of the DDI risk framework for this drug class.
) and a non-negligible portion of high level waste products and transuranic elements, which strongly contribute to the long-term radiotoxicity of the spent nuclear fuel. The recovery and recycling of uranium and plutonium were the first steps in developing a closed fuel cycle. Furthermore, a strong reduction of the volume, radiotoxicity and heat load of the spent nuclear fuel can be efficiently achieved. Despite the benefits of this first reprocessing approach, an amount of waste must be treated, stored and disposed of in a deep geological repository over a long period of time. Waste from reprocessing and spent nuclear fuel are classified as High Level Waste (HLW) according to the IAEA guidance due to the high emission of radioactivity and decay heat. The first reprocessing approach is based on the PUREX (Plutonium Uranium Reduction EXtraction) process, which is the standard and mature technology applied worldwide to recover uranium and plutonium from spent nuclear fuel at industrial scale. Following the dissolution of the spent fuel in nitric acid and the removal of uranium and plutonium, the generated secondary waste still contains fission and activation products along with transuranic elements that must be isolated from biosphere. Uranium and plutonium are recovered by the well-known tributylphosphate (TBP) ligand in a liquid-liquid extraction process.
Genetics is the study of genes, genetic variation, and heredity in organisms. It is an important branch in biology because heredity is vital to organisms' evolution. Gregor Mendel, a Moravian Augustinian friar working in the 19th century in Brno, was the first to study genetics scientifically. Mendel studied "trait inheritance", patterns in the way traits are handed down from parents to offspring over time. He observed that organisms (pea plants) inherit traits by way of discrete "units of inheritance". This term, still used today, is a somewhat ambiguous definition of what is referred to as a gene. Trait inheritance and molecular inheritance mechanisms of genes are still primary principles of genetics in the 21st century, but modern genetics has expanded to study the function and behavior of genes. Gene structure and function, variation, and distribution are studied within the context of the cell, the organism (e.g. dominance), and within the context of a population. Genetics has given rise to a number of subfields, including molecular genetics, epigenetics, population genetics, and paleogenetics. Organisms studied within the broad field span the domains of life (archaea, bacteria, and eukarya). Genetic processes work in combination with an organism's environment and experiences to influence development and behavior, often referred to as nature versus nurture. The intracellular or extracellular environment of a living cell or organism may increase or decrease gene transcription.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.